top of page

A Revolution Towards A Cure

We combine precision stem cell engineering, highly-scalable cell manufacturing, and NK-activating antibodies to unlock the full potential of Natural Killer cells
as a first line of defense against cancer.

Home: Welcome

Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2022, moving towards broad patient access to cancer-defeating cures."

Dr. Daniel Teper,

Cytovia Therapeutics CEO

Cytovia In The News

bottom of page